Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population

Renal Failure

Volumn 32, Issue 6, 2010, Pages 721-726

  Rao, Vinaya ^a   Fabrizi, Fabrizio ^a,b   Pennell, Phillip ^a   Schiff, Eugene ^a   De Medina, Maria ^a   Lane, Jeannine R ^c   Martin, Paul ^a   Ivor, Linda ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Gen Probe Incorporated   (United States)

Author keywords

Dialysis; HCV viremia; Hepatitis C virus; Transcription mediated amplification technology

Indexed keywords

ADULT; AGED; AMPLICON; ARTICLE; CONTROLLED STUDY; DIALYSIS; ENZYME IMMUNOASSAY; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS TRANSCRIPTION MEDIATED AMPLIFICATION ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77953573456     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.486499     Document Type: Article

References (38)

1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008;73(Suppl. 109):S1-S99.
2. Finelli L, Miller JT, Tokars JI, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.
3. Fissell RB, Bragg-Gresham JI, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOOPS. Kidney Int. 2004;65:2335-2342.
4. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus infection in hemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19: 904-909.
5. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. Am J Kidney Dis. 2007;18:1584-1593.
6. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: Meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
7. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-1902.
8. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOOPS). J Am Soc Nephrol. 2003;14:3270-3277.
9. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant. 2005;5:1452-1461. (Pubitemid 40839438)
10. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
11. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C virus infection, time on renal replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745-750.
12. Mitwalli AH, Alam A, Al-Wakel J, et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract. 2006;102:c72-c80.
13. Morales JM, Dominguez-Gil B, Sanz-Gajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipients on late renal allograft failure. Nephrol Dial Transplant. 2004;19:S72-S76.
14. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival. Transplantation. 2007;83:853-857.
15. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infection among chronic hemodialysis patients. MMWR. 2001;50:1-43.
16. Fabrizi F, Lunghi G, Colucci P, Finazzi S, Ponticelli C, Locatelli F. Reduced aminotransferase activity in patients with chronic renal failure not requiring dialysis: Impact on the evaluation of viral hepatitis. Am J Kidney Dis. 2001;28:1009-1015.
17. Silini E, Bono C, Cerino A, Piazza V, Solcia E, Mondelli MU. Virological features of hepatitis C virus infection in hemodialysis patients. J Clin Microbiol. 1993;31:2913-2917.
18. Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV negative hemodialysis patients. Nephrol Dial Transplant. 1998;13:1804-1808.
19. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infection in dialysis centers in the Netherlands: A national survey by serological and molecular methods. J Clin Microbiol. 1998;36:1711-1715.
20. Hinrichsen H, Leimenstoll F, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients: A multicenter study in 2796 patients. Gut. 2002;51:429-433.
21. Khan N, Aswad S, Shidban H, Aghajani M, Mendez R, Comanor L. Improved detection of HCV infection in hemodialysis patients using a new HCV RNA qualitative assay: Experience from a transplant center. J Clin Virol. 2004;30:175-182.
22. Rigopoulos E, Stefanidis I, Liaskos C, et al. HCV RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection on hemodialysis: Results from five hemodialysis units in central Greece. J Clin Virol. 2005;34:81-85.
23. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005;46:290-300.
24. Gaydos G, Quinn TC, Willis D, et al. Performance of the APTIMA Combo 2 assay for detection of Chlamydia Trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab protection. J Clin Microbiol. 2003;41:304-309.
25. Giachetti C, Linnen J, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and HCV RNA. J Clin Microbiol. 2002;40:2408-2419.
26. McDonough SH, Giachetti C, Yang Y, Kolk DP, Billyard E, Mimms L. High throughput assay for the simultaneous or separate detection of human immunodeficiency virus and hepatitis type C virus. Infusionsther Transfusionmed. 1998;25:164-169.
27. Arnold LJ, Hammond PW, Wiese WA, Nelson NC. Assay formats involving acridinium-ester-labeled probes. Clin Chem. 1989;35:1588-1594.
28. Nelson NC, Ben Cheikh A, Matsuda E, Becker M. Simultaneous detection of multiple nucleic acid targets in a homogeneous format. Biochemistry. 1996;35:8429-8438.
29. Kacian DL, Fultz TJ. Nucleic acid sequence amplification methods. US Patent 5 399 491. European patent EP 0 408 295, 1995.
30. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcriptionmediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology. 2000;32:818-823.
31. Comanor L, Anderson F, Ghany M, et al. Transcriptionmediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at the end of treatment. Am J Gastroenterol. 2001;96:2968-2972.
32. Comanor L, Elkin C, Leung K, et al. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcriptionmediated amplification in conjunction with the line probe assay. J Clin Virol. 2003;28:14-26.
33. Martin P, Fabrizi F. Hepatitis C and kidney disease. J Hepatol. 2008;49:613-624.
34. Noiri E, Nakao A, Oya A, Fujita T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis. 2001;37:38-42.
35. Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the Versant HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol. 2003;41:651-656. (Pubitemid 36184177)
36. Krajden M, Ziermann R, Khan A, et al. Qualitative detection of hepatitis C virus RNA: Comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol. 2002;40:2903-2907.
37. Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver Int. 2009;29: S9-S14.
38. Schijver I, Baron EJ. Labor and cost requirements of two commercial assays for qualitative molecular detection of hepatitis C virus. J Clin Microbiol. 2002;40:3476-3477.